Sanskriti Mbbs Chapagain
Sanskriti Mbbs Chapagain has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Abhigan Babu Shrestha
Patan Academy of Health Sciences Hospital, Lalitpur, Nepal
2 shared publications - Sajina Shrestha
Department of Medicine, KIST Medical College and Teaching Hospital, Imadol, Lalitpur, Nepal
2 shared publications Aayush Mbbs Shrestha
Department of Medicine, B.P. Koirala Institute of Health Science, Dharan, Nepal
1 shared publication- Abdelmonem Mbbs Siddiq
Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
1 shared publication Aimi Mbbs Shreshtha
Department of Medicine, Emilio Aguinaldo College, School of Medicine, Manila, Philippines
1 shared publication- Alish Bhandari
Nepal Army Institute of Health Sciences, Kathmandu, Nepal
1 shared publication
Latest Publications
- Open Access
- 16 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4467-4475
Endobronchial Zephyr valves for bronchoscopic lung volume reduction for severe emphysema: a systematic review and meta-analysis
Background: Chronic obstructive pulmonary disease (COPD) causes permanent lung damage and is a global health issue. Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr valves has increased COPD treatment choices for individuals with persistent symptoms despite maximal drug therapy. Objectives: This systematic review and meta-analysis evaluated available Zephyr valve data in severe emphysema patients. Data and methods: We searched Cochrane, PubMed, Google Scholar, Lilacs, and Science Direct extensively and included eight randomized control trials (RCTs). Results: This meta-analysis comprises 1083 patients 669 Zephyr valve-treated and 414 control. The mean difference in 6-minute walking distance was 37.53 meters (95% CI: 22.14–52.90, P < 0.001). Statistically significant improvements were also observed in FEV1 predicted percentage (mean difference: 13.64, 95% CI: 8.51–18.77, P < 0.001) and BODE index change (mean difference: −0.79, 95% CI: −1.33 to 0.26, P < 0.05), mMRC dyspnea scale (mean difference: −0.27, 95% CI: −0.55 to 0.02, P < 0.01) and residual volume (mean difference: −0.14, 95% CI: −0.64 to 0.35, P < 0.01). The quality of life measured by SGRQ also improved significantly (mean difference: −6.69, 95% CI: −9.69, −4.23, P < 0.001). While COPD exacerbation rates (OR:1.41, 95% CI: 0.87–2.30, P > 0.05) and pneumonia rates (OR: 1.72, 95% CI: 0.7–4.23, P > 0.05) were similar between valve and control groups, pneumothorax risk was significantly higher in the treatment arm (OR: 11.06, 95% CI: 4.10–29.80, P < 0.001). However, there was no significant difference in all-cause mortality between the groups (OR: 1.69; 95% CI: 0.53–5.38, P > 0.38). Conclusion: Zephyr valves may improve lung function, exercise capacity, and quality of life in patients suffering from severe emphysema. However, the increased risk of pneumothorax requires careful patient selection and rigorous post-intervention monitoring.
- 16 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4467-4475
Open AccessEndobronchial Zephyr valves for bronchoscopic lung volume reduction for severe emphysema: a systematic review and meta-analysis
Background: Chronic obstructive pulmonary disease (COPD) causes permanent lung damage and is a global health issue. Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr valves has increased COPD treatment choices for individuals with persistent symptoms despite maximal drug therapy. Objectives: This systematic review and meta-analysis evaluated available Zephyr valve data in severe emphysema patients. Data and methods: We searched Cochrane, PubMed, Google Scholar, Lilacs, and Science Direct extensively and included eight randomized control trials (RCTs). Results: This meta-analysis comprises 1083 patients 669 Zephyr valve-treated and 414 control. The mean difference in 6-minute walking distance was 37.53 meters (95% CI: 22.14–52.90, P < 0.001). Statistically significant improvements were also observed in FEV1 predicted percentage (mean difference: 13.64, 95% CI: 8.51–18.77, P < 0.001) and BODE index change (mean difference: −0.79, 95% CI: −1.33 to 0.26, P < 0.05), mMRC dyspnea scale (mean difference: −0.27, 95% CI: −0.55 to 0.02, P < 0.01) and residual volume (mean difference: −0.14, 95% CI: −0.64 to 0.35, P < 0.01). The quality of life measured by SGRQ also improved significantly (mean difference: −6.69, 95% CI: −9.69, −4.23, P < 0.001). While COPD exacerbation rates (OR:1.41, 95% CI: 0.87–2.30, P > 0.05) and pneumonia rates (OR: 1.72, 95% CI: 0.7–4.23, P > 0.05) were similar between valve and control groups, pneumothorax risk was significantly higher in the treatment arm (OR: 11.06, 95% CI: 4.10–29.80, P < 0.001). However, there was no significant difference in all-cause mortality between the groups (OR: 1.69; 95% CI: 0.53–5.38, P > 0.38). Conclusion: Zephyr valves may improve lung function, exercise capacity, and quality of life in patients suffering from severe emphysema. However, the increased risk of pneumothorax requires careful patient selection and rigorous post-intervention monitoring.
- 29 December 2023
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 100 (1183) , 279-282
mRNA vaccines as a revolutionary approach to combat cancer
Dear Editor, The development of mRNA vaccines has revolutionized the field of vaccination, offering a promising platform for preventing and treating various infectious diseases. mRNA vaccines are relatively inexpensive to produce and develop both humoral and cell-mediated response to diseases [ 1]. Despite its current use in infectious diseases, research into the use of mRNA vaccines for cancer treatment began much earlier, as early as 1995 when Conry and coworkers demonstrated that intramuscular injection of mRNA encoding carcinoembryonic antigens in mice induced anticancer immunity [ 2]. In 2009, Weide and his team conducted the first ever trial of mRNA vaccines for cancer in humans with metastatic melanoma, which resulted in an increased number of T cells directed against melanoma [ 3]. Since then, a number of preclinical as well as clinical studies have been conducted and several are still ongoing till date, to further explore the potential of mRNA vaccines in cancer treatment.
- 29 December 2023
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 100 (1183) , 279-282
mRNA vaccines as a revolutionary approach to combat cancer
Dear Editor, The development of mRNA vaccines has revolutionized the field of vaccination, offering a promising platform for preventing and treating various infectious diseases. mRNA vaccines are relatively inexpensive to produce and develop both humoral and cell-mediated response to diseases [ 1]. Despite its current use in infectious diseases, research into the use of mRNA vaccines for cancer treatment began much earlier, as early as 1995 when Conry and coworkers demonstrated that intramuscular injection of mRNA encoding carcinoembryonic antigens in mice induced anticancer immunity [ 2]. In 2009, Weide and his team conducted the first ever trial of mRNA vaccines for cancer in humans with metastatic melanoma, which resulted in an increased number of T cells directed against melanoma [ 3]. Since then, a number of preclinical as well as clinical studies have been conducted and several are still ongoing till date, to further explore the potential of mRNA vaccines in cancer treatment.
- Open Access
- 17 October 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (12) , 5852-5854
Vowst’s FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection
An abstract is unavailable. This article is available as a PDF only.
- 17 October 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (12) , 5852-5854
Open AccessVowst’s FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 4 October 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (11) , 5785-5788
Thanatophoric dysplasia in nonadherent to antenatal care in low middle income country: a rare case reports
Introduction and importance: Thanatophoric dysplasia is a rare, fatal, and sporadic form of skeletal dysplasia caused by a mutation in fibroblast growth factor receptor 3 (FGFR3). It is characterized by a conical thorax, platyspondyly (flat vertebral bodies), and macrocephaly. This disorder can be diagnosed antenatally as early as 13 weeks of gestation. Case presentation: The authors reported a case of thanatophoric dysplasia on USG in a 19 year old young consanguineous female in her second trimester of pregnancy. Ultrasound examination showed a clover leaf-shaped skull, a widened anterior fontanel, a coarse and edematous face, a flattened nasal bridge, a short neck, a low set of ears, shortening of both upper and lower limbs with short fingers, bowed thighs and legs, and a relatively narrow thorax. Clinical discussion: Lung hypoplasia, polyhydramnios, and hydrops in affected individuals lead to a poor prognosis. Hence, timely intervention should be done to avoid a poor prognosis. However, a mix of sonographic, genetic, histological, and autopsy studies are applied to make the most accurate diagnosis. Conclusion: The authors reported this case due to the rarity of this condition and the need for a systematic and multidisciplinary approach.
- 4 October 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (11) , 5785-5788
Open AccessThanatophoric dysplasia in nonadherent to antenatal care in low middle income country: a rare case reports
Introduction and importance: Thanatophoric dysplasia is a rare, fatal, and sporadic form of skeletal dysplasia caused by a mutation in fibroblast growth factor receptor 3 (FGFR3). It is characterized by a conical thorax, platyspondyly (flat vertebral bodies), and macrocephaly. This disorder can be diagnosed antenatally as early as 13 weeks of gestation. Case presentation: The authors reported a case of thanatophoric dysplasia on USG in a 19 year old young consanguineous female in her second trimester of pregnancy. Ultrasound examination showed a clover leaf-shaped skull, a widened anterior fontanel, a coarse and edematous face, a flattened nasal bridge, a short neck, a low set of ears, shortening of both upper and lower limbs with short fingers, bowed thighs and legs, and a relatively narrow thorax. Clinical discussion: Lung hypoplasia, polyhydramnios, and hydrops in affected individuals lead to a poor prognosis. Hence, timely intervention should be done to avoid a poor prognosis. However, a mix of sonographic, genetic, histological, and autopsy studies are applied to make the most accurate diagnosis. Conclusion: The authors reported this case due to the rarity of this condition and the need for a systematic and multidisciplinary approach.